206 related articles for article (PubMed ID: 37535881)
21. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
Subbiah V; Gouda MA; Iorgulescu JB; Dadu R; Patel K; Sherman S; Cabanillas M; Hu M; Castellanos LE; Amini B; Meric-Bernstam F; Shen T; Wu J
NPJ Precis Oncol; 2024 Mar; 8(1):62. PubMed ID: 38438731
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ
Oncology; 2016; 90(6):339-46. PubMed ID: 27207748
[TBL] [Abstract][Full Text] [Related]
23. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
[TBL] [Abstract][Full Text] [Related]
24. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
25. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
26. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
27. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
Paepegaey AC; Cochand-Priollet B; Louiset E; Sarfati PO; Alifano M; Burnichon N; Bienvenu-Perrard M; Lahlou N; Bricaire L; Groussin L
Thyroid; 2017 Apr; 27(4):587-590. PubMed ID: 28068878
[TBL] [Abstract][Full Text] [Related]
28. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
29. Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.
Starenki D; Park JI
J Clin Endocrinol Metab; 2013 Apr; 98(4):1529-40. PubMed ID: 23509102
[TBL] [Abstract][Full Text] [Related]
30. State of the art and future directions in the systemic treatment of medullary thyroid cancer.
Jager EC; Broekman KE; Kruijff S; Links TP
Curr Opin Oncol; 2022 Jan; 34(1):1-8. PubMed ID: 34669647
[TBL] [Abstract][Full Text] [Related]
31. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
Moccia M; Liu Q; Guida T; Federico G; Brescia A; Zhao Z; Choi HG; Deng X; Tan L; Wang J; Billaud M; Gray NS; Carlomagno F; Santoro M
PLoS One; 2015; 10(6):e0128364. PubMed ID: 26046350
[TBL] [Abstract][Full Text] [Related]
32. Genetics of medullary thyroid cancer: An overview.
Accardo G; Conzo G; Esposito D; Gambardella C; Mazzella M; Castaldo F; Di Donna C; Polistena A; Avenia N; Colantuoni V; Giugliano D; Pasquali D
Int J Surg; 2017 May; 41 Suppl 1():S2-S6. PubMed ID: 28506408
[TBL] [Abstract][Full Text] [Related]
33. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
34. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
35. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
36. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
Iervolino A; Iuliano R; Trapasso F; Viglietto G; Melillo RM; Carlomagno F; Santoro M; Fusco A
Cancer Res; 2006 Jun; 66(12):6280-7. PubMed ID: 16778204
[TBL] [Abstract][Full Text] [Related]
37. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.
Tiedje V; Ting S; Walter RF; Herold T; Worm K; Badziong J; Zwanziger D; Schmid KW; Führer D
Eur J Endocrinol; 2016 Sep; 175(3):173-80. PubMed ID: 27283290
[TBL] [Abstract][Full Text] [Related]
38. Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.
Chen W; Dream S; Leung PY; Wu PK; Wong S; Park JI
NPJ Precis Oncol; 2024 Feb; 8(1):39. PubMed ID: 38378752
[TBL] [Abstract][Full Text] [Related]
39. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
[TBL] [Abstract][Full Text] [Related]
40. Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?
Machens A; Spitschak A; Lorenz K; Pützer BM; Dralle H
Clin Endocrinol (Oxf); 2011 Dec; 75(6):801-5. PubMed ID: 21711375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
